CART Peptide

Most peptides studied for metabolic research are synthetic — engineered in a lab and introduced from the outside. CART is different. Cocaine- and amphetamine-regulated transcript (CART) is an endogenous neuropeptide your body already produces, discovered in 1995 when researchers found its mRNA upregulated by cocaine and amphetamine in rat brain [1] PMID: 9661247 .

The name is misleading. CART's primary research significance isn't addiction — it's appetite and energy balance. Research suggests CART acts as one of the brain's key anorexigenic signals, suppressing food intake when activated in hypothalamic circuits [2] PMID: 25352770 .

The defining feature is specificity. CART is co-expressed with POMC neurons in the arcuate nucleus — the same region that processes leptin signals — placing it at the crossroads of adiposity sensing and feeding behavior. Knockout studies in mice confirm the phenotype: remove CART, and animals gain excess fat mass on high-fat diets [3] PMID: 16102267 .

II. What is this compound?

CART (Cocaine- and Amphetamine-Regulated Transcript) is an endogenous neuropeptide encoded by the *CARTPT* gene, present across vertebrates with approximately 95% amino acid identity between rodents and humans [4] PMID: 25352770 .

The peptide is transcribed as two alternatively spliced mRNAs — proCART 1–89 and proCART 1–102 — but post-translational processing yields the biologically active fragments CART (55–102) and CART (62–102) [5] PMID: 9924797 . The full-length prepro-CART protein is 116 amino acids with a molecular weight of approximately 12,829 Da.

CART is expressed throughout the central nervous system, with particularly high density in brain regions governing homeostatic regulation: the arcuate nucleus, paraventricular nucleus, lateral hypothalamic area, and nucleus accumbens [6] PMID: 25352770 . It is also found in peripheral tissues — the gastrointestinal tract (myenteric plexus), pancreatic islets, vagal afferents, and white adipose tissue.

What makes CART structurally interesting to researchers is its evolutionary conservation. The near-complete sequence preservation between species suggests the peptide performs functions so physiologically critical that mutation has been strongly selected against over millions of years.

CART's receptor remains unidentified — a significant gap in the field. Signaling is known to involve Gi/o protein-coupled pathways (evidenced by pertussis toxin sensitivity), but the specific molecular target has resisted characterization [7] PMID: 25352770 . This limits the development of targeted pharmacological interventions and means most research relies on direct peptide administration or genetic models.

III. How it works

CART operates within hypothalamic circuits that the brain uses to balance energy intake against expenditure. Research suggests its primary anorexigenic mechanism involves signaling through Gi/o protein-coupled receptors in the arcuate nucleus and paraventricular nucleus [8] PMID: 25352770 , though the specific receptor identity remains unknown.

In the arcuate nucleus, CART is co-expressed with POMC/α-MSH neurons — the same population that mediates leptin's appetite-suppressing effects. Leptin positively regulates CART mRNA expression in this region [9] PMID: 16102267 , meaning when leptin rises (signaling adequate fat stores), CART production increases. This places CART downstream of adiposity sensing, functioning as one of the effector neuropeptides that translate metabolic state into feeding behavior.

The interaction with CCK adds a peripheral dimension. CART and cholecystokinin act synergistically to suppress feeding — CCK signals short-term satiety from the gut, and CART amplifies that signal centrally [10] PMID: 25352770 . This gut-brain coordination suggests CART integrates both immediate meal-related signals and longer-term energy status.

Site specificity complicates the picture. While central (intracerebroventricular) administration of CART consistently inhibits feeding, direct injection into specific hypothalamic nuclei — including the arcuate, ventromedial, and dorsomedial hypothalamus — can paradoxically stimulate food intake [11] PMID: 25352770 . This suggests CART participates in both anorexigenic and orexigenic circuits, with the net effect depending on which pathways predominate in a given context.

In the nucleus accumbens, CART modulates dopaminergic reward pathways, attenuating the locomotor and reinforcing effects of psychostimulants [12] PMID: 33757831 . This dual role — appetite regulation and reward modulation — positions CART at the intersection of homeostatic and hedonic feeding, an area of active research interest.

• Anorexigenic signaling via Gi/o protein-coupled receptors in hypothalamic nuclei
  PMID 25352770PMID 9661247
• Positive regulation by leptin in the arcuate nucleus, linking CART to adiposity signaling
  PMID 25352770PMID 16102267
• Modulation of dopaminergic reward pathways in the nucleus accumbens
  PMID 25352770PMID 33757831
• Synergistic appetite suppression with cholecystokinin (CCK) in vagal afferent signaling
  PMID 25352770

IV. Research Findings

The primary studied benefit of CART is appetite suppression. Central administration of CART peptide fragments consistently inhibits food intake in rodent models — one of the most reproducible findings in the neuropeptide feeding literature [13] PMID: 9661247 . This anorexigenic effect has been demonstrated across multiple experimental paradigms and injection sites.

Body weight regulation follows from this appetite effect. CART knockout mice gain excess body weight compared to wild-type littermates, particularly when fed a high-fat diet, with the phenotype driven primarily by increased fat mass [14] PMID: 16102267 . Some knockout models also show reduced lean mass. Notably, these animals exhibit a lower respiratory exchange ratio, indicating a metabolic shift toward fat oxidation over carbohydrate metabolism — a finding that suggests CART influences fuel selection beyond simple caloric intake.

Energy homeostasis is the broader framework. CART sits within the leptin-melanocortin pathway, functioning as one of several effector neuropeptides that translate hormonal signals about energy stores into behavioral and metabolic outputs [15] PMID: 25352770 . Its position in this circuit makes it a research target for understanding how the brain coordinates appetite, expenditure, and body composition.

Reward pathway modulation represents a distinct area of investigation. In the nucleus accumbens, CART attenuates psychostimulant effects on dopaminergic signaling [16] PMID: 33757831 . This has implications for understanding food reward — the hedonic component of eating that operates independently of homeostatic hunger — and potentially for research into addiction biology.

It is critical to emphasize that all documented benefits derive from preclinical animal studies and genetic models. No clinical trials have evaluated CART's effects in humans, and the peptide's therapeutic potential remains entirely speculative.

• appetite-suppression preclinical
  PMID 9661247PMID 25352770
• energy-homeostasis preclinical
  PMID 25352770PMID 33757831
• body-weight-regulation preclinical
  PMID 16102267PMID 16762453
• reward-pathway-modulation preclinical
  PMID 25352770

V. Dosage Context Explained

CART peptide has been studied exclusively in preclinical animal models. No human dosing data exists, and the peptide has never been administered to human subjects in controlled research settings.

In rodent studies, the most common administration route is intracerebroventricular (i.c.v.) injection, with reported doses ranging from 0.1 to 2.0 micrograms per injection [17] PMID: 9661247 . Intraperitoneal administration has also been used in some experimental designs, though central delivery remains the standard approach due to CART's primary role as a neuropeptide acting within the CNS.

The absence of a characterized receptor, combined with CART's site-specific and sometimes paradoxical effects on feeding, means that dose-response relationships are complex and context-dependent. What suppresses appetite when administered into one brain region may stimulate it in another [18] PMID: 25352770 .

Researchers working with CART must account for these variables in their experimental design. There are no established protocols, validated dosing guidelines, or standardized administration schedules for this peptide in any context.

• Administration Routes

  intracerebroventricular

  Range

  0.1–2.0 µg per injection in rodent models

  animal research only; no human dosing data exists

  PMID 9661247PMID 25352770

VI. Side Effects: Research Context

The safety profile of CART peptide in humans is entirely unknown. No clinical trials, toxicity studies, or systematic safety assessments have been conducted in human subjects.

In animal models, the most informative safety-relevant data comes from genetic knockout studies rather than exogenous administration. CART knockout mice develop increased body weight and fat mass, particularly on high-fat diets [19] PMID: 16102267 , which suggests that chronic CART deficiency promotes an obesogenic metabolic phenotype. Conversely, the effects of chronic CART excess have not been systematically characterized.

The site-specific paradoxical effects observed in intranuclear injection studies — where CART suppresses appetite in some brain regions but stimulates it in others [20] PMID: 25352770 — highlight the complexity of manipulating this system. Uncontrolled or non-targeted CART modulation could theoretically produce unpredictable effects on feeding behavior.

No contraindications have been formally established, but theoretical concerns exist for individuals with eating disorders, severe metabolic dysregulation, or conditions involving hypothalamic dysfunction. Without any human safety data, the risk profile of exogenous CART administration remains entirely speculative.

• no human safety data available
• CART knockout mice show increased body weight and fat mass on high-fat diets (preclinical)
• site-specific paradoxical orexigenic effects observed with direct intranuclear injection in rodents

VII. Frequently Asked Questions